{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T09:31:05Z","timestamp":1773048665394,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003968","name":"Iran National Science Foundation","doi-asserted-by":"publisher","award":["INSF-99008187"],"award-info":[{"award-number":["INSF-99008187"]}],"id":[{"id":"10.13039\/501100003968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.lfs.2020.118205","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T20:44:12Z","timestamp":1596833052000},"page":"118205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study"],"prefix":"10.1016","volume":"378","author":[{"given":"Faezeh Sadat","family":"Hosseini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massoud","family":"Amanlou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2020.118205_bb0005","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus\u2013infected pneumonia","author":"Li","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lfs.2020.118205_bb0010","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpha.2020.03.001","article-title":"Molecular immune pathogenesis and diagnosis of COVID-19","volume":"10","author":"Li","year":"2020","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.lfs.2020.118205_bb0015","first-page":"30","article-title":"An introduction to SARS coronavirus 2; comparative analysis with MERS and SARS coronaviruses: a brief review","volume":"49","author":"Taherizadeh","year":"2020","journal-title":"Iran. J. Public Health"},{"key":"10.1016\/j.lfs.2020.118205_bb0020","unstructured":"World Health Organization. Coronavirus Disease 2019 (COVID-19): Situation Report, 24."},{"key":"10.1016\/j.lfs.2020.118205_bb0025","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMp2000929","article-title":"A novel coronavirus emerging in China\u2014key questions for impact assessment","volume":"382","author":"Munster","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2020.118205_bb0030","author":"World Health Organization"},{"key":"10.1016\/j.lfs.2020.118205_bb0035","first-page":"1","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","author":"Wang","year":"2020","journal-title":"Cell Res."},{"issue":"6","key":"10.1016\/j.lfs.2020.118205_bb0040","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.3346\/jkms.2020.35.e79","article-title":"Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir\/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR","volume":"35","author":"Lim","year":"2020","journal-title":"J. Korean Med. Sci."},{"issue":"30","key":"10.1016\/j.lfs.2020.118205_bb0045","doi-asserted-by":"crossref","first-page":"8744","DOI":"10.1021\/bi0621415","article-title":"Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus","volume":"46","author":"Goetz","year":"2007","journal-title":"Biochemistry"},{"issue":"5","key":"10.1016\/j.lfs.2020.118205_bb0050","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.lfs.2020.118205_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2020.04.008","article-title":"Structural elucidation of SARS-CoV-2 vital proteins: computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase","author":"Mirza","year":"2020","journal-title":"J. Pharm. Anal."},{"issue":"3","key":"10.1016\/j.lfs.2020.118205_bb0060","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.drudis.2018.11.022","article-title":"The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions","volume":"24","author":"Polamreddy","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.lfs.2020.118205_bb0065","first-page":"1","article-title":"Structure of M pro from SARS-CoV-2 and discovery of its inhibitors","author":"Jin","year":"2020","journal-title":"Nature."},{"issue":"16","key":"10.1016\/j.lfs.2020.118205_bb0070","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"issue":"11","key":"10.1016\/j.lfs.2020.118205_bb0075","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","article-title":"ZINC 15\u2013ligand discovery for everyone","volume":"5","author":"Sterling","year":"2015","journal-title":"J. Chem. Inf. Model."},{"issue":"1","key":"10.1016\/j.lfs.2020.118205_bb0080","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open babel: an open chemical toolbox","volume":"3","author":"O\u2019Boyle","year":"2011","journal-title":"J. Cheminformatics"},{"issue":"3","key":"10.1016\/j.lfs.2020.118205_bb0085","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/07391102.2014.893203","article-title":"A new insight into mushroom tyrosinase inhibitors: docking, pharmacophore-based virtual screening, and molecular modeling studies","volume":"33","author":"Bagherzadeh","year":"2015","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.lfs.2020.118205_bb0090","series-title":"Discovery Studio Modeling Environment, Release 2017","author":"Dassault Syst\u00e8mes BIOVIA","year":"2016"},{"key":"10.1016\/j.lfs.2020.118205_bb0095","article-title":"Open babel: an open chemical toolbox","volume":"33","author":"O\u2019Boyle","year":"2011","journal-title":"J. Cheminformatics"},{"key":"10.1016\/j.lfs.2020.118205_bb0100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"10.1016\/j.lfs.2020.118205_bb0105","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1002\/jcc.23067","article-title":"Extension of the CHARMM general force field to sulfonyl-containing compounds and its utility in biomolecular simulations","volume":"33","author":"Yu","year":"2012","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.lfs.2020.118205_bb0110","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1021\/ci500020m","article-title":"g_mmpbsa\u2014a GROMACS tool for highthroughput MM-PBSA calculations","volume":"54","author":"Kumari","year":"2014","journal-title":"J. Chem. Inf. Model."},{"issue":"2","key":"10.1016\/j.lfs.2020.118205_bb0115","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/1574887109666140529222602","article-title":"Dasabuvir: a non-nucleoside inhibitor of NS5B for the treatment of hepatitis C virus infection","volume":"9","author":"Gentile","year":"2014","journal-title":"Rev. Recent Clin. Trials"},{"key":"10.1016\/j.lfs.2020.118205_bb0120","series-title":"Pharmacoinformatics and Molecular Dynamic Simulation Studies Reveal Potential Inhibitors of SARS-CoV-2 Main Protease 3CLpro","author":"Alamri","year":"2020"},{"key":"10.1016\/j.lfs.2020.118205_bb0125","series-title":"Repurposing Simeprevir, Calpain Inhibitor IV and a Cathepsin F Inhibitor Against SARS-CoV-2: A Study Using In Silico Pharmacophore Modeling and Docking Methods","author":"Francis","year":"2020"},{"key":"10.1016\/j.lfs.2020.118205_bb0130","article-title":"Comparative computational study of SARS-CoV-2 receptors antagonists from already approved drugs","author":"de Oliveira","year":"2020","journal-title":"ChemRxiv. Preprint."},{"key":"10.1016\/j.lfs.2020.118205_bb0135","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.csbj.2020.03.025","article-title":"Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model","volume":"18","author":"Beck","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"6","key":"10.1016\/j.lfs.2020.118205_bb0140","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1586\/17512433.2014.956091","article-title":"Simeprevir for the treatment of hepatitis C and HIV\/hepatitis C co-infection","volume":"7","author":"Flanagan","year":"2014","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118205_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104607","article-title":"Antiviral effects of simeprevir on multiple viruses","volume":"172","author":"Li","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.lfs.2020.118205_bb0150","series-title":"Potential Therapeutic Agents for COVID-19 Based on the Analysis of Protease and RNA Polymerase Docking","author":"Chang","year":"2020"},{"key":"10.1016\/j.lfs.2020.118205_bb0155","series-title":"Virtual Screening of an FDA Approved Drugs Database on Two COVID-19 Coronavirus Proteins. Chemrxiv","author":"Contini","year":"2020"},{"key":"10.1016\/j.lfs.2020.118205_bb0160","series-title":"Molecular Modeling Evaluation of the Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute Respiratory Syndrome Coronavirus 2 Proteases. bioRxiv","author":"Lin","year":"2020"},{"key":"10.1016\/j.lfs.2020.118205_bb0165","doi-asserted-by":"crossref","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","author":"Gao","year":"2020","journal-title":"BioSci. Trends"},{"issue":"0","key":"10.1016\/j.lfs.2020.118205_bb0170","first-page":"E014","article-title":"Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia","volume":"43","author":"Sun","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"issue":"2","key":"10.1016\/j.lfs.2020.118205_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005373","article-title":"A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis","volume":"11","author":"Love","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.lfs.2020.118205_bb0180","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejpb.2019.06.029","article-title":"Activity and pharmacokinetics of a praziquantel crystalline polymorph in the Schistosoma mansoni mouse model","volume":"142","author":"Lombardo","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"9","key":"10.1016\/j.lfs.2020.118205_bb0185","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00394-18","article-title":"Superior pyronaridine single-dose pharmacodynamics compared to artesunate, chloroquine, and amodiaquine in a murine malaria luciferase model","volume":"62","author":"Okoth","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.lfs.2020.118205_bb0190","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1021\/tx980148k","article-title":"Metabolism-dependent neutrophil cytotoxicity of amodiaquine: a comparison with pyronaridine and related antimalarial drugs","volume":"11","author":"Naisbitt","year":"1998","journal-title":"Chem. Res. Toxicol."},{"issue":"6","key":"10.1016\/j.lfs.2020.118205_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003878","article-title":"Machine learning models and pathway genome data base for Trypanosoma cruzi drug discovery","volume":"9","author":"Ekins","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"11","key":"10.1016\/j.lfs.2020.118205_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007890","article-title":"Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection","volume":"13","author":"Lane","year":"2019","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"2","key":"10.1016\/j.lfs.2020.118205_bb0210","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.lfs.2020.118205_bb0215","series-title":"Simeprevir Suppresses SARS-CoV-2 Replication and Synergizes With Remdesivir. bioRxiv","author":"Lo","year":"2020"},{"key":"10.1016\/j.lfs.2020.118205_bb0220","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3389\/fmolb.2017.00087","article-title":"Recent developments and applications of the MMPBSA method","volume":"4","author":"Wang","year":"2018","journal-title":"Front. Mol. Biosci."},{"issue":"23","key":"10.1016\/j.lfs.2020.118205_bb0225","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.2174\/09298673113209990001","article-title":"Virtual screening strategies in drug discovery: a critical review","volume":"20","author":"Lavecchia","year":"2013","journal-title":"Curr. Med. Chem."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520309577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520309577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T11:22:16Z","timestamp":1751196136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320520309577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":44,"alternative-id":["S0024320520309577"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2020.118205","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202002.0438.v1","asserted-by":"object"}]},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2020.118205","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"118205"}}